ENDRA Life Sciences Inc.: ENDRA Life Sciences Announces Pricing of Public Offering of Common Stock
ANN ARBOR, MI / ACCESSWIRE / December 15, 2020 / ENDRA Life Sciences Inc. ( ENDRA ) (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today announced the pricing of an underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per Common Share. In addition, ENDRA has granted the underwriter a 45-day option to purchase up to an additional 714,286 shares to cover over-allotments, if any. All of the shares are being offered by ENDRA.
ENDRA expects to receive gross proceeds from the offering of $5.0 million prior to deducting underwriting discounts, commissions and other offering expenses. If the underwriter exercises its over-allotment option in full, the gross proceeds would be approximately $5.5 million. The offering is expected to close on December 18, 2020, subject to the satisfaction of customary closing conditions.
ENDRA Life Sciences Granted Seventh Chinese Patent for its TAEUS(R) Platform Technology
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
ENDRA Life Sciences Announces Proposed Public Offering of Common Stock
bostonstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bostonstar.com Daily Mail and Mail on Sunday newspapers.
(2)
Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus Commercial Launch Plans Advance
ANN ARBOR, MI / ACCESSWIRE / December 15, 2020 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS
®), has recently been issued Chinese Patent ZL 2016 8 00267062 (the 062 patent) entitled Systems and Methods for Imaging Biological Tissue Structures from the Chinese Intellectual Property Office (SIPO). This is the seventh Chinese patent issued to ENDRA for its TAEUS technology. ENDRA s goal is to develop applications for our proprietary TAEUS technology in areas of high unmet clinical need and for which there are no practical existing tools. The recently issued 062 patent provides more robust intellectual property (IP) protection for our TAEUS platform in a key global market where an estimated 30% of its 1.4 billion citizens are affected by Non-Alcoholic Fatty Liver Disease, said Francois Michelon, ENDRA s chief exec